6mon
Medpage Today on MSNIvonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLCTo be eligible for the trial, patients had to have untreated locally advanced or metastatic NSCLC, ECOG performance status ...
The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...
A new deep learning model predicts which NSCLC patients will respond to immunotherapy, outperforming some traditional ...
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...
Hosted on MSN11mon
Soluble immune checkpoint factors in blood as potential biomarkers of therapeutic efficacy for ICI cancer immunotherapyis currently used as a biomarker to determine the efficacy of PD-1 or PD-L1 targeted treatment in patients with NSCLC. However, due to heterogeneity of tPD-L1 expression and insufficient ...
The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...
Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...
in non-small cell lung cancer, which applies to England and Wales, NICE said the drug could be recommended for patients who express high levels of PD-L1, but want BMS to provide more data on these ...
Risk - EGFR-mutant NSCLC is a very unusual next shot on goal for cosibelimab With the lone exception of the IMpower150 regimen that incorporated targeted therapy, chemotherapy, and PD-L1 treatment ...
As it relates to Summits' running of the HARMONi-7 study, using ivonescimab as a monotherapy to target first-line metastatic NSCLC patients with high PD-L1 expression, Akeso with HARMONi-2 has ...
When used in conjunction with the PD-L1 IHC 28-8 pharmDx as a companion test, in the European Union: (a) resectable NSCLC patients with PD-L1 expression ≥1% and at high risk of recurrence may be ...
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications Agilent Technologies Inc. (NYSE: A) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results